Date: Thursday, February 3, 2022
Time: 2pm ET / 11am PT
Duration: 1 Hour
Improving the discovery of novel drugs with artificial intelligence
Last year, Toronto-based Deep Genomics used artificial intelligence to scan 200,000 genomes from people with a variety of diseases, and in so doing identified a disease target—Wilson’s—as well as potential drug candidates to treat it. The drug is now advancing towards human trials.
Several other life sciences companies are now using AI throughout the development process to identify drug candidates, predict how they’ll perform in animals and humans, and more. Even well-established drug developers are implementing AI across their operations, including Roche’s Genentech, which recently teamed up with a Stanford University spinout to use AI to find new ways to drug hard-to-reach disease targets.
We’ll cover the newest and most innovative AI solutions that have been developed for the life sciences industry, gathering tips from technology developers and pharma executives on using these new tools to boost R&D. Topics include:
- How AI can be used to improve the ability to predict which compounds are likely to make it to late-stage trials.
- Generating drug leads by applying machine learning to genomics, proteomics, metabolomics and lipidomics.
- Best practices for choosing and partnering with technology developers to maximize the benefits of AI in drug development.